ANXA1 expression has been reported to be negatively correlated with prostate cancer, esophageal squamous cell carcinoma (ESCC) [51,52], oral squamous cell carcinoma [53,54], cervical cancer [55], laryngeal cancer [56,57], nasopharyngeal cancer [58], and breast cancer [59]. This evidence concerns the gene ANXA1 and laryngeal carcinoma.